

November 21, 2024

**Otsuka Pharmaceutical Factory launches “KIDPAREN<sup>®</sup> Injection,”  
the amino acid, glucose, electrolyte, fat, and multivitamin injection for  
high calorie parenteral nutrition of patients with chronic kidney disease**

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shuichi Takagi; hereinafter, “Otsuka Pharmaceutical Factory”) will launch “KIDPAREN<sup>®</sup> Injection,” the amino acid, glucose, electrolyte and multivitamin injection for high calorie parenteral nutrition of patients with chronic kidney disease, on December 3, 2024.

This product is a kit formulation of total parenteral nutrition that combines amino acids, glucose, electrolytes (excluding potassium and phosphorus) and vitamins (in accordance with the FDA 2000 formulation<sup>\*1</sup>) in a 1,050 mL 3-chamber bag that provides 1,500 kcal and is directed at the patients with chronic kidney disease who need to restrict fluid.

Total parenteral nutrition (TPN) is also called high calorie nutrition. It is a method of administering concentrated nutrition solution through a major central vein close to the heart and is used for patients in poor nutritional conditions or who are unable to eat and drink for a long period of time (not less than a week).

Oral or enteral feeding of the patients with chronic kidney disease may be impossible or insufficient due to various complications, etc.,<sup>\*2</sup> and they may have to depend on TPN, a combination of TPN base solution for kidney disease, amino acid solution for kidney disease, TPN multivitamin, electrolytes, etc. However, this method has posed a problem that the feeding volume tends to be large to provide necessary nutrients.

This Product, with the volume of solution reduced as much as possible, satisfies the energy requirements set in the Dietary Recommendations for Chronic Kidney Disease<sup>\*3</sup>, and supplies amino acids to build as much protein as possible, glucose, electrolytes (except potassium and phosphorus), and vitamins (in accordance with the FDA 2000 formulation). It enables preparation of mixing various ingredients aseptically by breaking the center seal before use. We hope this Product will allow more options of injections for TPN management of the patients with chronic kidney disease and reduce the burden on the healthcare setting.

Otsuka Pharmaceutical Factory continue to provide information and products useful for appropriate nutrition management, aiming to be the best partner for patients and healthcare professionals in the field of clinical nutrition.

Based on the corporate philosophy of “Otsuka-people creating new products for better health worldwide,” the Otsuka Group is dedicated to contributing to the health of people around the world.

- \*1. Vitamin formulation for parenteral nutrition issued by the Food and Drug Administration (FDA) in 2000.
- \*2. Gastrointestinal bleeding, aspiration pneumonia, bile capsule inflammation, consciousness disorder by cerebrovascular disorders, mental eating disorders, anorexia by uremia, diarrhea (severe), ileus, disuse syndrome, preoperative and postoperative care, etc.
- \*3. Edited by the Japanese Society of Nephrology: Dietary Recommendations for Chronic Kidney Disease 2014, The Japanese Journal of Nephrology, 2014; 56 (5): 553-599

## Product Information

Brand name	KIDPAREN <sup>®</sup> Injection
Regulatory classification	Prescription drug
Indications	Provision of water, electrolytes, calories, amino acids, and vitamins for patients with chronic kidney disease who are unable or difficult to take nutrients orally or enterally and have to depend on total parenteral nutrition (limited to those with or likely to have hyperkalemia or hyperphosphatemia)
Dosage and administration	<p>Immediately before use, break the center seal between the upper and lower chambers, and also break the yellowish-brown mini chamber within the upper chamber simultaneously. Mix the three solutions thoroughly before use.</p> <p>The standard maintenance dosage for adults is 1,050 mL, administered via continuous intravenous infusion into a central vein over 24 hours.</p> <p>Since this drug is a preparation containing a high concentration of glucose, attention should be paid to glucose tolerance, liver function, etc., especially at the start of the administration. The administration should be started at a low rate (roughly about half of the maintenance dose), and the daily dose should be gradually increased to reach the maintenance dose.</p> <p>The dosage should be adjusted according to the patient's condition, age, and body weight.</p>
Packaging	<p>1,050 mL×10 bags</p>
Storage	Store at room temperature, protected from light
Expiration date	18 months
Price	2,269 yen /1,050mL (1 kit)
Manufactured and distributed by	Otsuka Pharmaceutical Factory, Inc.
Comarketed by	Otsuka Pharmaceutical Co., Ltd.

## Company Profile

### Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969 (founded September 1, 1921)
Capital	:	80 million yen
Representative	:	Shuichi Takagi, President, and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,318 (as of December 31, 2023)
Business Description	:	Manufacture, sale, import and export of pharmaceuticals, medical devices, and functional foods with a focus on clinical nutritional products.
URL	:	<a href="https://www.otsukakj.jp/en/">https://www.otsukakj.jp/en/</a>